Advertisement

Topics

Brainstorm Cell Therapeutics Company Profile

11:20 EST 12th December 2018 | BioPortfolio

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). The adult stem cells are used to create healthy new brain-like cells that replace or support the diseased cells. Patients treated with the Company’s NurOwn™ therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.

Location

110 East 59th Street
New York
10022
United States of America

Contact

Phone: (212)-557-9000
Fax: (212)-581-8958
Email: info@brainstorm-cell.com


News Articles [2260 Associated News Articles listed on BioPortfolio]

BrainStorm Cell Therapeutics Announces Positive Interim Safety Analysis

On Thursday (August 23), BrainStorm Cell Therapeutics announced its Phase 3 trial for NurOwn in patients with ALS will be able to continue with no changes. The post BrainStorm Cell Therapeutics Announ...

BrainStorm to Host Tomorrow a Conference Call to Announce Its Right To Try Policy

NEW YORKand PETACH TIKVAH, Israel, June 25, 2018/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell Read more...

BrainStorm will not provide ALS therapy under U.S. Right to Try act

TEL AVIV (Reuters) - BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing ...

Exclusive: BrainStorm will not provide ALS therapy under U.S. Right to Try act

TEL AVIV (Reuters) - BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing...

BrainStorm submits IND for progressive multiple sclerosis drug trial

BrainStorm Cell Therapeutics submitted to the FDA an investigational new drug application seeking approval for a midstage stu -More- 

BrainStorm gibt Neuigkeiten hinsichtlich der „Right to Try -Gesetzgebung bekannt

  Webcast und Telefonkonferenz heute um 8.30 Uhr US-Ostküstenzeit NEW YORKund PETACH TIKVA, Israel, 26. Juni 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:  BCLI), Read mor...

BrainStorm Reverses Course On Selling ALS Medication Under Right-to-Try Legislation

Less than a week after floating the idea of offering its experimental ALS therapy NurOwn to patients under the recently-passed Right-to-Try legislation, Israel-based BrainStorm Cell Therapeutics has r...

BrainStorm Expands Leadership Team on Heels of Right-to-Try Controversy

The senior leadership team at Israel-based BrainStorm Cell Therapeutics, Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.

PubMed Articles [3208 Associated PubMed Articles listed on BioPortfolio]

Assessing the Effects of Ripasudil, a Novel Rho Kinase Inhibitor, on Human Corneal Endothelial Cell Health.

To determine how the Rho kinase inhibitor, ripasudil, affects metabolic function and cell viability in donor human corneal endothelial cells (HCECs).

Curing cancer by cancer function.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

Dysregulating ClpP: From Antibiotics to Anticancer?

In this issue of Cell Chemical Biology, Wong et al. (2018) identify several dysregulators of a key mitochondrial protease: casein lytic protease P (ClpP). These dysregulators were found to trigger pr...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.

Clinical Trials [6623 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2192 Associated Companies listed on BioPortfolio]

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult st...

BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

More Information about "Brainstorm Cell Therapeutics" on BioPortfolio

We have published hundreds of Brainstorm Cell Therapeutics news stories on BioPortfolio along with dozens of Brainstorm Cell Therapeutics Clinical Trials and PubMed Articles about Brainstorm Cell Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Brainstorm Cell Therapeutics Companies in our database. You can also find out about relevant Brainstorm Cell Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...


Corporate Database Quicklinks



Searches Linking to this Company Record